Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Core Insights - Corvus Pharmaceuticals, Inc. will host a conference call and webcast on January 20, 2026, to report results from cohort 4 of a Phase 1 clinical trial evaluating soquelitinib for moderate to severe atopic dermatitis [1] - Soquelitinib is an investigational oral small molecule drug that selectively inhibits ITK and is currently in a registration Phase 3 clinical trial for relapsed/refractory PTCL [3] Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on ITK inhibition as a novel immunotherapy approach for various immune diseases and cancers [3] - The company is developing multiple clinical-stage candidates targeting a range of cancer indications [3] Conference Call Details - The conference call can be accessed via a toll-free domestic number or an international number, and a live webcast will be available on the investor relations section of the Corvus website [2] - A replay of the webcast will be accessible on the Corvus website for 60 days following the event [2]